10X GENOMICS ($TXG) posted quarterly earnings results on Thursday, August 7th. The company reported earnings of $0.28 per share, beating estimates of -$0.38 by $0.66. The company also reported revenue of $172,910,000, beating estimates of $140,808,412 by $32,101,588.
You can see Quiver Quantitative's $TXG stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
10X GENOMICS Insider Trading Activity
10X GENOMICS insiders have traded $TXG stock on the open market 7 times in the past 6 months. Of those trades, 1 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $TXG stock by insiders over the last 6 months:
- ALAN MATEO purchased 40,000 shares for an estimated $445,572
- SERGE SAXONOV (Chief Executive Officer) has made 0 purchases and 3 sales selling 22,377 shares for an estimated $218,279.
- BENJAMIN J. HINDSON (See Remarks) has made 0 purchases and 2 sales selling 12,058 shares for an estimated $112,723.
- ADAM TAICH (Chief Financial Officer) sold 4,044 shares for an estimated $33,562
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
10X GENOMICS Hedge Fund Activity
We have seen 164 institutional investors add shares of 10X GENOMICS stock to their portfolio, and 126 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 4,987,195 shares (+235.6%) to their portfolio in Q1 2025, for an estimated $43,538,212
- MILLENNIUM MANAGEMENT LLC added 4,386,327 shares (+442.5%) to their portfolio in Q1 2025, for an estimated $38,292,634
- FMR LLC removed 3,561,295 shares (-26.5%) from their portfolio in Q1 2025, for an estimated $31,090,105
- BANK OF AMERICA CORP /DE/ added 2,012,390 shares (+307.2%) to their portfolio in Q1 2025, for an estimated $17,568,164
- BROWN CAPITAL MANAGEMENT LLC removed 1,843,960 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $16,097,770
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,530,004 shares (-85.9%) from their portfolio in Q1 2025, for an estimated $13,356,934
- RA CAPITAL MANAGEMENT, L.P. removed 1,335,154 shares (-40.7%) from their portfolio in Q1 2025, for an estimated $11,655,894
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
10X GENOMICS Government Contracts
We have seen $9,429,006 of award payments to $TXG over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- CONSUMABLES FOR 10X GENOMICS CHROMIUM CONTROLLER AND 10X GENOMICS CHROMIUM X INSTRUMENTS: $897,016
- PROSTHETIST, PROSTHETIST TECHNICIAN, AND PROSTHETIST ASSISTANT IN THE DEPARTMENT OF SURGICAL SERVICES AND R...: $818,603
- 10X GENOMICS XENIUM ANALYZER/10X GENOMICS VISIUM CYTASSIST: $345,109
- CHROMIUM CELL KITS: $315,314
- CHROMIUM CELL KITS: $315,314
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
10X GENOMICS Analyst Ratings
Wall Street analysts have issued reports on $TXG in the last several months. We have seen 8 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 06/24/2025
- RBC Capital issued a "Outperform" rating on 06/12/2025
- Scotiabank issued a "Sector Outperform" rating on 06/04/2025
- Morgan Stanley issued a "Overweight" rating on 05/19/2025
- Stephens & Co. issued a "Overweight" rating on 05/15/2025
- Goldman Sachs issued a "Sell" rating on 05/12/2025
- Canaccord Genuity issued a "Buy" rating on 05/12/2025
To track analyst ratings and price targets for 10X GENOMICS, check out Quiver Quantitative's $TXG forecast page.
10X GENOMICS Price Targets
Multiple analysts have issued price targets for $TXG recently. We have seen 13 analysts offer price targets for $TXG in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Derik De Bruin from B of A Securities set a target price of $13.0 on 06/26/2025
- Luke Sergott from Barclays set a target price of $13.0 on 06/24/2025
- Michael Siperco from RBC Capital set a target price of $65.0 on 06/12/2025
- Eric Winmill from Scotiabank set a target price of $50.0 on 06/04/2025
- Tejas Savant from Morgan Stanley set a target price of $18.0 on 05/19/2025
- Mason Carrico from Stephens & Co. set a target price of $14.0 on 05/15/2025
- Dan Leonard from UBS set a target price of $12.0 on 05/13/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
